Hi Butcherano, I would say use that TOTAL 40% or greater reduction in Proteinuria as a guide for a clinically meaningful benefit, but the 2 trials are different in both design & drug/s obviously.
Ann: Application for quotation of securities - DXB, page-114
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.5¢ |
Change
0.010(2.02%) |
Mkt cap ! $277.5M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 52.0¢ | 48.5¢ | $2.668M | 5.293M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49800 | 50.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 103810 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
50.5¢ |
Change
0.010 ( 2.81 %) |
||||
| Open | High | Low | Volume | ||
| 50.5¢ | 52.0¢ | 48.5¢ | 3521721 | ||
| Last updated 15.57pm 03/06/2024 ? | |||||
| DXB (ASX) Chart |